Transcript Pearl Organics Limited

Wanbury Limited
February 2006
1
Disclaimer
This presentation is made purely for information. We have tried
to give relevant information which we believe will help in
understanding the Company. The viewers may use their own
judgement and are advised to make their own calculations
before deciding on any matter based on the information given
herein. While every care is taken to verify the accuracy of the
information given in this presentation, neither the Company
nor its officials would in any way be liable for any action
taken or not taken by the viewers or the users of this
presentation or for any claims, losses etc. This is not a
prospectus or document soliciting investment in the Company
Wanbury Limited
Overview
3
Our Vision …
To become a global pharmaceutical company with
presence in Formulations and APIs ….
… a market capitalisation in excess of Rs.1000 cr
……by March 2009
Wanbury Limited
Business Model
BULK
BUSINESS
DOMESTIC
FORMULATIONS
FORMULATIONS
OVERSEAS
Existing
Export Focus
3 Plants
Existing
Focus on Domestic
Ethical Brands
New Product Intros.
Existing
None
Planned
Expansion
Addl. plant
Planned
Brand acquisitions
Addition of division in
medium term
Strategic Associations
Planned
European
Generics
Wanbury Limited
Bulk Business
6
Snapshot

World’s largest producer of Metformin

We sell to leading global generic players in regulated markets

Exporting to over 50 countries

Over 14 products ... Of these over 8 products for US and Europe

3 API facilities with 2 USFDA approved for multi product in Maharashtra and AP

Over 24 products within 18 months and foray in contract manufacturing

Aggressive pitch of DMF Filings through a strengthened Research Base. New
R&D centre set up at Navi Mumbai for Process Research
Wanbury Limited
Key Customers

Apotex, Canada

Mega Pharma, Mexico

Torr Pharma, USA

Pure Pharma, Europe

Mylan, USA

Salutos, Germany

Barr Laboratories, USA

Wessex, UK

TEVA, Israel

Tabuk, Saudi Arabia

Dexxon, Israel

Pharmire, Sourth Korea

Pliva, USA

Ranbaxy, India

Remedica, Cyprus

Strides Arcolabs

Drageno Pharma, Germany


Moleculus Mexico


Pfizer


Glenmark,India
Sun Pharma, India
Cadila Pharmaceuticals
Alkem, India
Wanbury Limited
Product Portfolio
Existing

Metformin

Gabapentene Int.

Salsalate

Tramadol

Ibuprofen


Glucosamine

Mefenamic Acid

Introductions
this year
Pipeline
for 2007




Amitryiptyline
Promethazine
Sertraline
Paroxetine Hemihydrate
Carvedilol
Desloratidine
Losartan Potassium

Meloxicam

Gliclazide

Fluvastatin

Pantaprazole

Glybenclamide

Fluconazole

Gabapentene

Hydrochlorthyzide

Clopidogrel
….a market size of over $ 2 Bn
Wanbury Limited
Product Pipeline
DMFs Available
DMFs in Process
Scale up
Metformin HCl
Losartan Potassium Carvedilol
Tramadol Hydrochloride (EDQM)
Clopidogrel Hydrogen sulphate
Tramadol Hydrochloride( US)
Carvedilol
Risperidone
Promethazine Hydrochloride
Diphenhydramine Hydrochloride
Venlafaxine
Sertraline Hydrochloride
Glucosamine Sulfate Kcl
Amitriptyline Hydrochloride
Glucosamine Sulfate NaCl
Ondansetron
Glimepiride
Lab Stage
New Products
Pantaprazole
Meloxicam
Methoxsalen
Fluvastatin
Irbesartan
Glybenclamide
Gliclazide
Fluconazole
Venlafaxine
Paroxetine Hydrochloride
Metformin HCl DC grade 90%
Metformin HCl DC grade 95%
Ibuprofen DC grade 90%
Glucosamine HCl
Ibuprofen
Mefenamic acid
Wanbury Limited
Our Research Strategy
Process
Research
Pharma
Research
APIs for Regulated
markets /Emerging
markets
and Contract
manufacturing
Time Frame
Existing
By March ’05
By Nov ‘06
NDDS
Development of
novel platforms
for Specialty
Generics and IPR
Development of
ANDAs and
finished dosages for
regulated markets
Activity
Scientists
Outlay
Expertise
Existing set up Formulations
and R&D research
15
-
APIs for Regulated Markets
New centre for Process
Research
45
Rs. 5cr
DMFs and Contract
Manufacturing
New Centre for Research
70
Rs.15cr
Formulations Research + NDDS
Wanbury Limited
Our Research Strategy
NCE
NDDS
Development of novel platforms
for Speciality Generics and IPR
Pharma Research
Development of ANDAs and
finished dosages for regulated markets
Process Research
APIs for Regulated markets /Emerging markets
and Custom Synthesis
Wanbury Limited
Stage I- Process Research Center

Area of Focus
– Widening DMF pipeline for regulated markets (10 DMFs over 15 m)
– New Product introductions for emerging markets
– Intermediate manufacturing for innovators
– Development for Contract Manufacturing
– Widened coverage of therapeutic area
_ Custom synthesis

Research Set-up
– Existing facilities to be strengthened and new Research Facility being set up
in Navi Mumbai
– Team comprising 20 scientists with 4 PhDs in Organic Chemistry
– Well equipped analytical Lab comprising HPLCs, GCs, FTIR, UV Visible,
Particle size analyser etc
– Team expandable to 60 scientists over 24 months
Wanbury Limited
Stage II Research Center

Area of Focus
– Development of Formulations
– Dossier preparations and ANDA filings for regulated markets
– Development of platforms for Novel Drug Delivery for Speciality Generics
– Clinical Research Capabilities for carrying out bio equivalence studies

Research Set-up
– New facility for a closed loop research lab to be set up close to
Mumbai/Pune
– Full service Analytical Lab with NMR, HPLCs, GCs, FTIRs,
,XRD,DSC,GCMS,LCMS.
– Lab Management Systems
– Clinical Research capabilities starting with capabilities for bio equivalence
studies
– Facilities for In vivo studies
– Animal House for In vitro studies
Wanbury Limited
Contract Manufacturing


Wanbury is well positioned to emerge as an outsourcing
partner of choice due to our quest for quality, desire for
innovation, a highly efficient supply chain management and
optimal utilization of capacities.
Wanbury is in an unique position to offer a single point of
contract for R&D, process development and production.
Availability of dedicated, adequately trained and highly
qualified manpower in R&D , production and QA/RA.
Wanbury Limited
Custom Synthesis

Custom synthesis
– Already carrying out synthesis for European customers
– Expanding team of scientific officers to procure business
– New systems to be incorporated in the R&D to strengthen
IPR protection and facilitate business
Wanbury Limited
Reaction Capabilities















In addition to general reactions we are specialised in the following
Azidation
Bromination
Reactions involving Butyl Lithium
Cyanation
Chiral chemistry
Griganard
Sodium metal reactions
Metal hydride reductions
Optical Resolution
High Pressure Reactions
Hydrogenation
High Temperature Reactions (250°C)
High Vacuum Distillations
Low Temperature Reactions (-80°C)
Wanbury Limited
Formulation Business
18
Our Formulation Business




Founded in 1865 by Dr. George Wander in Berne, Switzerland
Wander has been in the Indian market since late forties with it’s cold
and nutrition products …originally a subsidiary of Sandoz
Now a Wanbury division with 310 professionals, 16 brands, 24
Distributors and about 1200 stockists across the country.
Independent Formulation Research and Development Centre at
Chembur recognised by Govt. of India

Strong focus on Pediatrics, Gynecology and Orthopedics

Growth through niche neutraceuticals led lifestyle segment
Wanbury Limited
Brands
Doctor Segment
Pediatrics
Gynecologists
Orthopedics
Consulting Physicians
GPs
Brands
C-Pink
Coriminic
Zeva
Nurture
SetCal
Gemron
Cemax-O
Cefcare
Oftek
Ofgyl
Nock -2
Adtrol
Clamist
Senasof
Wanbury Limited
Growth Strategy
21
Growth Strategy
LEVERAGE ON ….

Existing Satisfied Customers

Strong Marketing Skills

In-house technical competence

In-house Research expertise
Global Generics
Contract
Manufacturing
Strategic Alliance
Product
Life Style Division
Introductions
Acquisitions
Expansion
Improve PCPM

Experience in managing and
building US FDA approved plants
4 Years
Wanbury Limited
Management
23
Board of Directors

Mr. K Chandran
..ED

Mr. K.R.N. Moorthy
..ED

Mr. N. K. Puri
..Independent

Dr. P. L. Tiwari
..Independent

Mr. A. Bongirwar
..Independent

Mr. S. Bhattacharya ..Nominee(EXIM)
Wanbury Limited
Advisory Board

Mr. K. R. N. Moorthy is supported by an
advisory board:
– Mr. S. Balsekhar,

Ex-Chairman Roussel Pharmaceutical
– Dr. Indira Parekh,

Dean IIM Ahmedabad
– Group Directors
Wanbury Limited
Human Resources
Human Resources
Services and
Corporate Office,
75
Manufacturing On Contract, 160
R&D (API), 30
Formulation Sales
and Marketing ,
310
QC, QA and RA,
30
Manufacturing On Rolls, 225
Wanbury Limited
Key Personnel
BOARD of DIRECTORS
ADVISORY BOARD
K R N MOORTHY
ED & President APIs/Formulations
ASHOK SHINKAR
Director C F (M&A)
S R Jagannathan
Sr. VP Operations
Dr S Samant
V P Marketing
S Jayaram
V P Legal
Dr. Pulla Rao
Head QA and Regulatory
M.K. PADMANABHAN
National Sales Manager
P. Gupta
Company Sec.
V S Ayare
R&D
Mahesh Kolatkar
AGM IT
Vijayan Nair
GM Finance
Raman Iyer
GM Marketing
Dr Shankar
GM R&D
Kurush Dubash
Head Training
Surina Iyer
DGM HR
Wanbury Limited
Management
– Key personnel
Name
Designation
Experience
Mr. Ashok Shinkar
Director Corporate Finance
12 years with J.M.Morgan Stanley and SSKI Corporate Finance
Mr. S. R. Jagannathan SVP - Technical
28 years with Ranbaxy, Sanmar Chemplast, Shasun Chemicals and
Drugs, Matrix Laboratories
Dr Y Pulla Rao
SVP - QA and Regulatory
26 years with IDPL, SOL Pharma, Neuland Laboratories, Jubliant
Organics
Dr.Rajaram S Samant VP–
Marketing 8 Yrs with USV, Ranbaxy, Emcure
(Formulations)
Mr. S. Jayaram
VP – Legal
37 years with Crompton Greaves, Innovation Equipment, M&M,
Boots Pharma & Khandelwal Builders
Mr.M.K.Padmanabhan National Sales Manager
22 years with Ranbaxy, Mircro Lab
Mr. Vijayan Nair
GM Finance
24 years with Concept, Lupin, Parekh Dyechem
Dr. S. Shankar
GM – R&D
17 years with Calyx, Chemspec, IPCA, E.Merck
Mr. Raman Iyer
GM – Exports (API)
22 years with Concept, Ranbaxy, Alkem, Vorin, Aarti
Mr. Kurush F. Dubash
Head of Training
32 years with Wockhardt Pharma & Pfizer Ltd
Mr. Anand Dhoka
DGM -Commercial
Mr. Sabu Daniel
DGM – Marketing (API)
28 years with Maharashtra Polybutenes, EPIC, Sriman Group,
Cyanides & Chemicals
16 years with Aarti Drugs, Rajasthan Glyoxal
Mrs. Surina Iyer
DGM – HR
11 Yrs with L&T, Lavasa Corporation
Mr. Pankaj B. Gupta
Company Secretary
4 years with Grasim Industries Ltd, Global Boards Ltd
Ms. Janki Desai
Marketing Manager
9 years with GlaxoSmithKline & Cipla Ltd
Mr. Mahesh Kolatkar
AGM - IT
20 years with Baan Infosystem, Raymonds etc.
Wanbury Limited
HR Thrust .. Focus Areas

Talent Acquisition – Selection Techniques

Team Alignment & Rationalization

Measuring Performance & Assessing Potential

Compensation Benchmarking

Capability Building and Leadership Development

Career Development & Succession Planning

Create Think Tank ~ Innovative Practices

Communication – Openness – Transparency - Speed

System Orientation
Building Human Capital …..
For Superior & Competitive Results
Wanbury Limited
Wanbury’s VALUES

Respect for People

Innovation

Sense of Urgency

Result Focus

Leadership

Team Work

Customer Focus
Wanbury Limited
Mission statement
We at Wanbury, want to make a company that employees are proud of
and committed to, where every employee has an opportunity to
contribute, learn, grow and advance on merit.
We are dedicated in improving quality of our employees by continuously
providing high quality training and development.
We will continue to establish a business model, which is predictable,
sustainable, growth oriented and profitable.
We will always worship exceptional and superior performance. We will
continuously challenge status-quo / maintenance and simultaneously
encourage and recognize stretch and growth.
We will work hard not only to satisfy but delight our customers (both
internal and external).
We will strive to make Wanbury one of the preferred employers.
Wanbury Limited
Thank You
32